119 related articles for article (PubMed ID: 28895610)
21. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
22. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine.
Johnston D; Bystryn JC
Vaccine; 2006 Mar; 24(11):1958-65. PubMed ID: 16310898
[TBL] [Abstract][Full Text] [Related]
23. Calcineurin subunit B activates dendritic cells and acts as a cancer vaccine adjuvant.
Li J; Guo J; Su Z; Hu M; Liu W; Wei Q
Int Immunol; 2011 May; 23(5):327-34. PubMed ID: 21447603
[TBL] [Abstract][Full Text] [Related]
24. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.
Aranda F; Llopiz D; Díaz-Valdés N; Riezu-Boj JI; Bezunartea J; Ruiz M; Martínez M; Durantez M; Mansilla C; Prieto J; Lasarte JJ; Borrás-Cuesta F; Sarobe P
Cancer Res; 2011 May; 71(9):3214-24. PubMed ID: 21402711
[TBL] [Abstract][Full Text] [Related]
26. Immunological adjuvant effect of the peptide fraction from the larvae of Musca domestica.
Chen L; Zhang J; Sun H
BMC Complement Altern Med; 2015 Dec; 15(1):427. PubMed ID: 26630909
[TBL] [Abstract][Full Text] [Related]
27. Ginsenoside Rg1 Activates Dendritic Cells and Acts as a Vaccine Adjuvant Inducing Protective Cellular Responses Against Lymphomas.
Huang Y; Zou Y; Lin L; Zheng R
DNA Cell Biol; 2017 Dec; 36(12):1168-1177. PubMed ID: 29058460
[TBL] [Abstract][Full Text] [Related]
28. Immunological adjuvant effect of Boswellia serrata (BOS 2000) on specific antibody and cellular response to ovalbumin in mice.
Gupta A; Khajuria A; Singh J; Singh S; Suri KA; Qazi GN
Int Immunopharmacol; 2011 Aug; 11(8):968-75. PubMed ID: 21371582
[TBL] [Abstract][Full Text] [Related]
29. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions.
Redondo P; del Olmo J; López-Diaz de Cerio A; Inoges S; Marquina M; Melero I; Bendandi M
J Invest Dermatol; 2007 Jul; 127(7):1673-80. PubMed ID: 17380112
[TBL] [Abstract][Full Text] [Related]
30. Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8(+) T-cell Response and Protects Mice from Melanoma.
Qiu Z; Huang H; Grenier JM; Perez OA; Smilowitz HM; Adler B; Khanna KM
Cancer Immunol Res; 2015 May; 3(5):536-46. PubMed ID: 25633711
[TBL] [Abstract][Full Text] [Related]
31. The allergy adjuvant effect of particles - genetic factors influence antibody and cytokine responses.
Nygaard UC; Aase A; Løvik M
BMC Immunol; 2005 Jun; 6():11. PubMed ID: 15967044
[TBL] [Abstract][Full Text] [Related]
32. Co-assembled Supramolecular Nanofibers With Tunable Surface Properties for Efficient Vaccine Delivery.
Wang Z; Ren C; Shang Y; Yang C; Guo Q; Chu L; Liu J
Front Chem; 2020; 8():500. PubMed ID: 32850613
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-10-treated dendritic cells do not inhibit Th2 immune responses in ovalbumin/alum-sensitized mice.
Bellinghausen I; Sudowe S; König B; Reske-Kunz AB; Knop J; Saloga J
Int Arch Allergy Immunol; 2006; 141(1):61-9. PubMed ID: 16804328
[TBL] [Abstract][Full Text] [Related]
34. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
[TBL] [Abstract][Full Text] [Related]
35. OVA-bound nanoparticles induce OVA-specific IgG1, IgG2a, and IgG2b responses with low IgE synthesis.
Yanase N; Toyota H; Hata K; Yagyu S; Seki T; Harada M; Kato Y; Mizuguchi J
Vaccine; 2014 Oct; 32(45):5918-24. PubMed ID: 25211769
[TBL] [Abstract][Full Text] [Related]
36. Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.
Gableh F; Saeidi M; Hemati S; Hamdi K; Soleimanjahi H; Gorji A; Ghaemi A
J Biomed Sci; 2016 Jan; 23():16. PubMed ID: 26811064
[TBL] [Abstract][Full Text] [Related]
37. Novel Injectable Pentablock Copolymer Based Thermoresponsive Hydrogels for Sustained Release Vaccines.
Bobbala S; Tamboli V; McDowell A; Mitra AK; Hook S
AAPS J; 2016 Jan; 18(1):261-9. PubMed ID: 26589309
[TBL] [Abstract][Full Text] [Related]
38. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
[TBL] [Abstract][Full Text] [Related]
39. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
40. Potential of Translationally Controlled Tumor Protein-Derived Protein Transduction Domains as Antigen Carriers for Nasal Vaccine Delivery.
Bae HD; Lee J; Jin XH; Lee K
Mol Pharm; 2016 Sep; 13(9):3196-205. PubMed ID: 27454469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
